about
Study of GLS-5700 in Dengue Virus Seropositive AdultsSafety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy AdultsRandomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease VaccineMelatonin versus Placebo in Breast CancerSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's DiseaseEvaluation of the Single-Use Pre-Filled AutoinjectorCultured White Cells Plus Interleukin-2 to Treat Advanced Kidney CancerPilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural MesotheliomasPhase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerAnti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent GlioblastomaAZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerDurvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHNA Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast CancerNivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerDaratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaCombination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung CancerDurvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerUse of Busulfan as Conditioning Agent for a Second Stem Cell TransplantPioglitazone Therapy for Chronic Granulomatous DiseaseUltraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal MatrixGene Therapy for X-linked Chronic Granulomatous DiseaseHigh Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseHaploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant CyclophosphamideGene Therapy for X-CGDGene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in ChildrenGene Therapy for Chronic Granulomatous Disease in KoreaEvaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve AdultsZika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and TolerabilityZIKA Vaccine in Naive SubjectsStudy in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic AreaA Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule StudyRandomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy AdultsVRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy AdultsSafety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in HumansSafety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients
P6099
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacyTranslation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trialOnline CBT II: A Phase I Trial of a Standalone, Online CBT Treatment Program for Social Anxiety in StutteringPhase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeRandomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patientsThe myth of equipoise in phase 1 clinical trialsAn open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trialPhase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancerA phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumoursA phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neuPhase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosisPhase I trial of temozolomide (CCRG 81045: M&B; 39831: NSC 362856)Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritisIndividualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus)Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialPhase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcomaA phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancerStudy of GLS-5700 in Dengue Virus Seropositive AdultsBiomarkers in phase I-II chemoprevention trials: lessons from the NCI experiencePhase I trials of antitumour agents: fundamental conceptsDesigns of drug-combination phase I trials in oncology: a systematic review of the literaturePhase I (first-in-man) prophylactic vaccine's clinical trials: Selecting a clinical trial siteNovel methodologic approaches to phase I, II, and III trialsStatistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsPhase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical TrialPhase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult VolunteersClinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt TumorsPhase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activationPhase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis
P921
Q26762063-6FA92860-8A0D-45D0-A219-CCC737315282Q26780919-1260055F-38D6-4AD0-B337-D793DE206ADAQ28837195-7b217ed4-41a2-7487-c900-09e3fffa7feaQ28922621-B862DB64-C89C-4BF6-8E2D-84082D45DE1DQ45287449-6F228674-E0A0-4DF1-8F57-107B930C1C8CQ57949859-7b436e92-4a37-1cf2-6342-43697fba1a2dQ58407406-24be19a3-429c-6940-a3d3-d350d4863acfQ58407540-09458954-8406-4E2C-ABD4-94C7900F9922Q58407557-A9176360-4AA6-4252-9592-64156BBA59E9Q58407578-c43c466c-436e-797d-ca37-59cc4ca7ddb6Q58407688-0B493D84-7EE9-4DDF-AD1C-077D4AF9DC44Q58407740-D48876F8-38FC-49D9-A5B8-FD9CC3139CA9Q58407815-9bb94d9e-4edf-12b8-6c37-2926c0f88b2dQ58845207-fc2d8034-4c66-1635-cd5f-a5a523c482a9Q58846466-16f8ef1e-4896-9913-6c0e-327016c4eb97Q58847174-DC42C0B3-3E19-444C-9A9D-1D375FC1262EQ58849419-0D698745-1E10-420B-9878-43624BC8221CQ58850257-e7f9bcd0-49ad-bb6e-f00f-3bdc5aa39203Q59772555-7B6F4643-0BB3-4C86-8E49-422A57B1671BQ60392210-D65223CE-5D7B-4809-B895-0C4C395E45FCQ60501328-04A16F9C-93F2-429B-A9D5-32FB34FC4D9BQ60501340-94892BDE-6878-40C1-81A3-D015A5FA482FQ60502449-0C92151C-6716-4590-BAC9-4119131289B6Q60502451-5E382A4B-55C8-4B6D-8A55-D4E3FEC08B4BQ60502456-2F75E20F-3D03-40D9-8236-0EBCA0A3F26AQ60502459-ABBE8CC1-2C78-465A-A54A-30319DEC3540Q60502462-CEF7CDC4-5FFB-44A1-96C4-05F5E68CA53AQ60502463-18582023-31AD-4EF3-AEA7-CB109C56A573Q60502467-32EEEAD8-5388-44D9-81D2-15054ECB3F07Q60563288-A643F8DA-307E-4CDA-BC55-B87C3F9FFC6AQ60563293-79EBD8AE-5D1F-4000-B09A-B4D1467F41D1Q60563298-868F5E89-BDB0-47E0-B6B2-5F2078F99394Q60563300-11895D8C-4BC7-4C44-9590-362A2382A477Q60563303-747B5ACB-D362-4FE8-978E-9CBCDA5A154AQ60563306-B2417306-F9D3-4CF0-AE66-5D3E73BBE403Q60563307-0349A69A-F3A1-4EAD-BF8A-D99640604619Q60563313-63DB1229-8905-4866-A921-F95F4C875D17Q60563327-70BE07FB-56FB-45DE-A48B-03B2B45A981DQ60563329-45D4CD8D-D7D1-4E44-A8DB-8766870896F1Q60563332-71CC4ADB-AADF-43E7-8F93-68EC77663EC8
P6099
Q21135264-77ACFE23-790C-46BF-A9E4-40E5AFE37D1AQ21245483-C301B54C-FADD-4ECB-9FAA-0E684A3085F2Q22241406-7B9BDBD6-6138-45BB-B431-A859CD5F149FQ24289281-41154195-6A65-4580-9AD8-61231E0C4CB9Q24535495-6E727388-FA09-4D06-B4E4-59A5ADCFFD14Q24569794-6FC2FB0E-C0DA-4347-8696-0A3AB91CDED0Q24601525-FABCD8BE-DBF2-417C-8A71-755984D944B9Q24608049-66907FF4-1672-4471-B57A-6E8824C6F7ECQ24625197-955688EF-8FDC-4FDA-804C-C1724F07AACBQ24648321-FCC2194C-6FE8-4A71-B7DE-964A132992F3Q24649530-6CA84649-2C17-40C4-AA1A-042D3BB5AFBBQ24657081-AFE375BF-7B61-4212-B1B8-8B14706911E3Q24683819-28AA6C86-1767-4AEE-829F-6E6D6DDEBFBEQ24800647-77F31A41-79CC-44AA-8C73-2DC3F5B819ABQ24800799-11C72DDE-F350-4FFA-8877-E849955D1CEEQ24801506-9AF56E54-2354-440E-AFDE-8685ED9A1B80Q24808685-CDD46B32-0338-4741-8113-CA25DF21D95CQ25255692-81785DA6-0775-4C7F-9428-B8D74E24EC13Q26762063-F9ED46AD-2DB2-49EF-AB5C-276170903063Q26774585-8F9B6DDE-CFF0-4672-B5D1-0DA1234B73E9Q26865346-F10CA52B-B66A-4C6F-9E43-918870434944Q26996348-769A3AD1-5170-4F75-BC39-D25B07A810C5Q26998593-C593F63D-308D-4459-BAE4-512E5FDAE7B4Q27012934-48981C3F-38D9-44F0-8619-598EC1215AA5Q27023178-4B2D4159-3A12-42AD-8137-A3D55A18039BQ27310843-FDF7F1E5-2FC9-40E1-AF0A-284F536562CBQ27488963-6401B034-BB7E-414D-B74B-47C7C8E61827Q27490989-52531A6C-4902-45F6-9321-D1746AF3962DQ27690634-83B55C80-B34F-411B-8A65-E1C983A5AFA9Q27701564-0D8DC41E-04A9-4A45-AB6B-ABCE0F128484Q27851478-95569AE1-1CD0-4F1E-B46A-2E0215B47CC5Q27851801-8A348239-9A97-4206-81D3-64082D1CF6C6Q27851852-74CB4FAF-6E69-4762-A30E-3E4547EBD503Q27851856-C681DD94-A8CE-4C7A-BA01-E79B07E81BCEQ27852097-2C65A5C9-0C24-4A70-9B8D-2E4B284D1DA2Q27852954-027F4BBA-82C5-436F-93E3-5570D6A48260Q27853112-DB447F3C-51C2-4557-9DA8-8A1603EDD32CQ27853360-8A97E3C1-B78B-4EE6-A3AA-118647299753Q28141319-68CE0A80-DBCC-4563-82C7-419990F96509Q28143909-D09F9304-A0A9-42E2-80E8-11D3B982816F
P921
description
earliest phase of a clinical trial, aimed at studying safety and dosage
@en
fase más temprana de un ensayo clínico, dirigida a estudiar la seguridad y dosis
@es
počáteční fáze klinického hodnocení nového léku
@cs
健常人を対象に被験薬の安全性や薬物動態を検討する、治験の段階
@ja
name
Phase-I-Studie
@de
essai clinique phase 1
@fr
fase 1 d'assaig clínic
@ca
fase 1 de ensayo clínico
@es
klinische proeffase I
@nl
phase I clinical trial
@en
studie I. fáze
@cs
фаза I клиничког тестирања
@sr
第I相試験
@ja
type
label
Phase-I-Studie
@de
essai clinique phase 1
@fr
fase 1 d'assaig clínic
@ca
fase 1 de ensayo clínico
@es
klinische proeffase I
@nl
phase I clinical trial
@en
studie I. fáze
@cs
фаза I клиничког тестирања
@sr
第I相試験
@ja
altLabel
1. fáze klinického hodnocení
@cs
Klinik Phase 1
@de
Klinik Phase I
@de
Phase-1-Studie
@de
fáze I klinického hodnocení
@cs
phase 1 clinical trial
@en
phase 1 trial
@en
phase 1
@en
phase I trial
@en
phase I
@en
prefLabel
Phase-I-Studie
@de
essai clinique phase 1
@fr
fase 1 d'assaig clínic
@ca
fase 1 de ensayo clínico
@es
klinische proeffase I
@nl
phase I clinical trial
@en
studie I. fáze
@cs
фаза I клиничког тестирања
@sr
第I相試験
@ja
P672
P279
P3712
P672
V03.175.250.100